Color Doppler Ultrasound And Fibroscan Technology For Chronic Liver Fibrosis Diseases

PART IEvaluation of Fibrosis of Chronic Hepatic Diseases byColor Doppler UltrasonographyObjective: To discuss the value of Color Doppler ultrasonography in the evaluationof fibrosis of chronic hepatic diseases.Methods:180patients of chronic hepatitis B were enrolled. The patients weredivided into4groups according to the pathologic fibrosis results through liver biopsy:0grade(S0,40cases)，1grade(S1,38cases)，2grade(S2,37cases)，3grade(S3,40cases)，4grade(S4,35cases).The following parameters were obtained by Color Dopplerultrasonography: main portal vein diameter(mPVD)、mean velocity of main portalvein(mPVm)、blood flow of main portal vein（mPBF）、congestion index of portal vein（CI）、diameter of splenic vein（SVD）、mean velocity of splenic vein（sVm）、bloodflow of splenic vein.The results were compared with pathologic fibrosis stage throughliver biopsy.Results: There were significant differences in mPVD、mPVm、CI and sVD amongthe groups(P<0.05). There was significant difference between any group with theother(all P<0.05). The mPVD,SVD and CI were positively correlated with liver fibrosisstage(r=0.44，0.41，0.42，all P<0.05). The mPVm was negatively correlated with liverfibrosis stage（r=-0.43，P<0.05）. Conclusion: Being as a routine imaging method, the parameters of portal andsplenic veins obtained by Color Doppler ultrasonography ultrasound can be a help inevaluation of fibrosis extent of chronic hepatic diseases. PART IIEvaluation of Fibrosis of Chronic HepaticDiseases by FibroScanObjective: To discuss the value of Fibroscan in the evaluation of fibrosis ofchronic hepatic diseases.Methods:360patients of chronic hepatic diseases were enrolled. The patientswere divided into4groups: hepatitis B carriers group (112cases)，chronic hepatitis B（CHB） group(130cases)，liver cirrhosis group(118cases).The values ofFibroScan(FS) were obtained by Fibroscan.The data were compared among thegroups.Results: There were significant differences in FS among the groups(P<0.05).There was significant difference between any group with the other(all P<0.05). Indetail,CHB group> hepatitis B carriers group(P<0.05)，liver cirrhosis group> hepatitisB carriers group(P<0.05)，liver cirrhosis group>CHB group(P<0.05).Conclusion: The extent of fibrosis of chronic hepatic diseases can be evaluatedaccurately by Fibroscan. It is a great help in early diagnosis and treatment of fibrosis ofchronic hepatic diseases.